semaglutide alzheimers fails to slow Alzheimer's disease progression ๐ข BREAKING: New Alzheimer's Trial
Description
PMID: 40289060 ACR Convergence 2025: New Research Highlights Potential of GLP-1 Therapies in Rheumatic Disease Management
Thyroid function from birth to adolescence in Prader-Willi syndrome
00459-9/asset/8ec1c90a-c705-400f-abe4-6e4235385280/main.assets/gr2_lrg.jpg)
95%CI 0.380.98) (Sattar et al., 2021)
In light of this potential significant safety issue, the development of Lotiglipron has been discontinued, meaning the drug did not progress to further clinical trial stages to evaluate its efficacy and safety
The key actions of GLP-1 include : Stimulating insulin release (but only when blood sugar is high, reducing hypoglycaemia risk)
